ClinicalTrials.gg
RecruitingNCT07783919DUAL AFUpdated Nov 20, 2026

Single-Shot Versus Focal Dual-Energy Pulsed Field-Based Ablation for Atrial Fibrillation

An interventional study of Catheter Ablation for Atrial Fibrillation in Atrial Fibrillation (AF), sponsored by Marien Hospital Herne. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Marien Hospital Herne · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 417 studies in Atrial Fibrillation with a site in Germany — 60 open to participants now, 88 under way, 4 of them phase 3. Atrial Fibrillation · Germany.

Planned enrollment
119th of 284
268 · median 200
Started
2026
with 12 others
No phase
166 of 417
31 open now
Primary completion
2027-08
later than 50 of 87 live
Registered
415th of 417
by date

Among the 417 studies in Atrial Fibrillation with a site in Germany, this one is the 119th largest by planned enrollment of the 284 interventional ones that give a count, is one of 13 that started in 2026, is one of 166 with no phase, reaches primary completion later than 50 of the 87 other live ones, and was the 415th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

60 of the 417 studies in Atrial Fibrillation with a site in Germany are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 417 studies in Atrial Fibrillation with a site in Germany, or all of them as a file.
02

Study summary

Comparison of single-shot PFA systems with focal dual-energy (PFA/RF) in patients at high risk of atrial fibrillation recurrence.

Read the detailed description

Catheter ablation via pulmonary vein isolation (PVI) is an established therapy for symptomatic paroxysmal and persistent atrial fibrillation. In recent years, pulsed-field ablation (PFA) has emerged as an innovative ablation technology. Unlike thermal ablation using radiofrequency or cryoablation, PFA relies on irreversible electroporation of the cell membrane, thereby enabling the selective ablation of cardiomyocytes while largely sparing adjacent structures such as the esophagus, phrenic nerve, and pulmonary veins. Clinical studies and registry data have demonstrated high efficacy and a favorable safety profile for PFA.

Various catheter systems are now available for performing PVI via PFA. These include single-shot systems, which facilitate rapid pulmonary vein isolation through a standardized and efficient workflow. Additionally, focal dual-energy catheters have been developed that combine pulsed-field ablation and radiofrequency ablation within a single catheter. These systems allow for tailored lesion delivery using electroanatomical mapping systems and may offer advantages, particularly in cases of complex anatomy or additional arrhythmogenic substrate.

Both single-shot and focal dual-energy systems have demonstrated high acute success rates and promising clinical outcomes in studies to date. However, there are currently no direct, prospective, randomized comparisons between the two ablation strategies. In particular, it remains unclear whether there are differences between the two approaches regarding long-term freedom from atrial arrhythmias, procedural efficiency, or safety.

Patients with persistent atrial fibrillation and those with a high comorbidity burden face an increased risk of atrial arrhythmia recurrence despite successful pulmonary vein isolation. While single-shot systems enable a standardized, rapid, and reproducible ablation procedure, focal dual-energy systems-due to their greater flexibility-may offer advantages in cases of complex anatomy and for individually tailored ablation strategies.

To date, there are no randomized clinical trials directly comparing these two ablation approaches. In particular, there is a lack of prospective data regarding patients at high risk for atrial arrhythmia recurrence. This study aims to bridge this evidence gap by investigating whether ablation using single-shot PFA is non-inferior to ablation using a focal dual-energy catheter in terms of clinical efficacy in patients at high risk of recurrence.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • First-time pulmonary vein isolation
  • Symptomatic atrial fibrillation:

    • Paroxysmal atrial fibrillation (≥ 2 episodes in the last 6 months) and one of the following:

CHA2DS2VA score ≥ 2, ≥ 1 cardioversion in the last 6 months or Left atrial (LA) diameter ≥ 45 mm

o or persistent atrial fibrillation (≥ 1 episode in the last 6 months)

Exclusion criteria

Exclusion Criteria:

  • Atrial fibrillation due to reversible or non-cardiac causes
  • Severe mitral or tricuspid valve regurgitation requiring therapy
  • Previous left atrial endocardial or epicardial ablation
  • Pregnancy or breastfeeding
  • Lack of opportunity for reliable study participation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
268 participants (estimated)

Study arms

  • Active comparator
    Single shot PFA-based Ablation for AF

    Procedure: Catheter Ablation for Atrial Fibrillation

  • Placebo comparator
    Focal Dual-Energy-based Ablation for Atrial Fibrillation

    Procedure: Catheter Ablation for Atrial Fibrillation

Interventions

  • ProcedureCatheter Ablation for Atrial Fibrillation

    PFA-based Catheter Ablation for Atrial Fibrillation (PFA single shot vs. focal dual-eregy)

06

What researchers measure

Primary outcomes

  1. Freedom from atrial arrhythmias during follow-up

    Rate of participants with freedom from atrial arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia) during follow-up, excluding the blanking period

    Time frame: 365 days, excluding the blanking period

Secondary outcomes

  1. Freedom from atrial fibrillation/atrial tachycardia

    Rate of participants with freedom from atrial fibrillation and rate of participants with freedom from atrial flutter or atrial tachycardia) during follow-up, excluding the blanking period

    Time frame: 365 days, excluding the blanking period

  2. First-pass isolation rate and acute PVI success

    Rate of first-pass isolation of the pulmonary veins as well as rate of acute procedural success of the PVI

    Time frame: Day of the ablation (periprocedural)

  3. Procedural durations

    Total procedural time, fluoroscopy time, LA dwell time

    Time frame: Day of the procedure (periprocedural)

  4. Correlation between procedural parameters and clinical efficacy

    Correlation between procedural parameters (first-pass isolation rate, acute procedural success rate, total procedural time, fluoroscopy time) with clinical efficacy (rate of freedom from atrial arrhythmias (AF, AFL, AT)) during follow-up, excluding the blanking period

    Time frame: 365 days, excluding the blanking period

  5. Electroanatomical evaluation in the event of potential re-ablation

    In the event of a potential re-ablation, the rate of durable PVI will be assessed

    Time frame: day of the potential re-ablation (periprocedural)

  6. Patient-reported outcome measures (PROMs)

    AFEQT questionnaire

    Time frame: 365 days, excluding the blanking period

  7. Occurrence of serious adverse events

    Time frame: 365 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 10 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2026
First posted
Aug 25, 2026
StartActual
Oct 26, 2026was Sep 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
Marien Hospital Herne is now Recruiting
Nov 20, 2026
Start date
Sep 1, 2026→Oct 26, 2026 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    Marien Hospital Herne is now Recruiting
    Start date Sep 1, 2026→Oct 26, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07783919
Lead sponsor
Marien Hospital Herne
Responsible party
Dimitrios Bismpos (Dr. med. Dimitrios Bismpos, Marien Hospital Herne) — Principal investigator
First posted
Aug 25, 2026
Start date
Oct 26, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Dimitrios Bismpos, Dr.med.
Contact
Dimitrios.Bismpos@elisabethgruppe.de
+49023234995609

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion